News
Novo Nordisk announces CEO transition as share price slips
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight loss drugs.
8hon MSN
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
Everyday Health on MSN2d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback